Inventor
WARING MICHAEL JAMES
GB21 patents
⚠️ This page may combine multiple inventors who share the name “WARING MICHAEL JAMES”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ASTRAZENECA AB
13 patentsUS7842694B2Nov 30, 2010
Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
ASTRAZENECA AB11 citations92
US7642263B2Jan 5, 2010
Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
ASTRAZENECA AB16 citations92
US7642259B2Jan 5, 2010
Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
ASTRAZENECA AB18 citations92
US7745475B2Jun 29, 2010
Heteroaryl benzamide derivatives as GLK activators
ASTRAZENECA AB14 citations83
US9944650B2Apr 17, 2018
[1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases
ASTRAZENECA AB5 citations81
US7671060B2Mar 2, 2010
Heteroaryl benzamide derivatives
ASTRAZENECA AB13 citations81
US10766905B2Sep 8, 2020
[1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases
ASTRAZENECA AB1 citations70
US10407432B2Sep 10, 2019
[1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases
ASTRAZENECA AB3 citations70
US11407755B2Aug 9, 2022
[1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases
ASTRAZENECA AB0 citations59
US7902200B2Mar 8, 2011
Chemical compounds
ASTRAZENECA AB4 citations56
US7977328B2Jul 12, 2011
Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
ASTRAZENECA AB0 citations51
US7964725B2Jun 21, 2011
Heteroarylbenzamide derivatives for use in the treatment of diabetes
ASTRAZENECA AB0 citations49
US7943607B2May 17, 2011
Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
ASTRAZENECA AB0 citations41